Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. The Private Securities Litigation Reform Act of 1995 permits this discussion. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial … Novocure is due to issue an interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer. Ashley Cordova - Senior Vice … ... Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021) ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy.The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in … The safety and effectiveness of TTFields therapy for NSCLC has not been established. Novocure LUNAR Description LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. “We believe that treatment with TTFields is bigger than one cancer type. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and … The science of Tumor Treating Fields extends beyond glioblastoma. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 “We are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.”. LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Final data from phase 3 pivotal LUNAR trial … ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Therefore, you should not rely on any such factors or forward-looking statements. 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. The LUNAR trial design was based on preclinical findings that suggest TTFields may act synergistically with certain taxanes and enhance the efficacy of immune checkpoint inhibitors. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Specifically, it was being explored in patients who progressed during or … This website intends to use cookies to improve the site and your experience. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. Novocure also plans to highlight key clinical and product development … We have revised our Privacy Policy that is in effect as of May 25, 2018. Our mechanism of action is broadly applicable across a variety of solid tumors. Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. Professor Yoram Palti founded Novocure in 2000. In addition, the trial design was informed by Novocure’s phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum based therapy. Lung Cancer. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer More Information. Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. NovoCure Ltd. ClinicalTrials.gov Identifier: NCT03780569 Other Study ID Numbers: ICH-1 : First Posted: December 19, 2018 Key Record Dates: Last Update Posted: December 20, 2018 Last Verified: December 2018 We have since accomplished many significant milestones. Following the study, Novocure announced that it was testing the combination of Tumor Treating Fields with immune checkpoint inhibitors in its Phase III LUNAR trial in patients with stage 4 NSCLC. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022) NovoCure is also anticipating interim data from some Phase III trials. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. Please click here to access it. Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. Company Participants. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. We completed phase 2 pilot trials in pancreatic cancer and ovarian cancer, and shared the topline results at our research and development day in … Lung cancer is the leading cause of cancer-related death in the United States. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [LUNAR Centers]. http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. For more information on the trial design, visit ClinicalTrials.gov. Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. NovoCure (NASDAQ:NVCR) Q2 ... tumor treating fields and anti-PD-1 therapies as a second-line treatment for stage IV non-small cell lung cancer in our Lunar trial… Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. Broad applicability of the mechanism of action. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. In February 2017, we enrolled the first patient in our phase 3 pivotal LUNAR trial studying TTFields in patients with advanced non-small cell lung cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … It also plans to issue an interim analysis of a phase three pivotal PANOVA-3 trial in locally advanced pancreatic cancer as well as an interim analysis of a phase three pivotal INNOVATE-3 trial in recurrent ovarian cancer. Any forward-looking statements herein speak only as of the date hereof. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. Patient images reflect the health status of the patients at the time each photo or video was taken. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. By continuing to browse the site you are agreeing to accept our use of cookies. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. “We designed this trial to test TTFields with two of the currently available standard of care treatments for advanced NSCLC following failure of platinum-based therapy, opening the trial to more patients with this disease,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Given these risks and uncertainties, any or all of these forward-looking statements provide novocure’s expectations... Stage IIIB and IV NSCLC of all lung cancers the date hereof of events... Uncertainties, any or all of these forward-looking statements metastases from NSCLC and in advanced NSCLC, provided! ( TTFields ) therapy is not approved for the treatment of adult with! The quarter ended June 30, 2020 8:00 AM ET and your experience like., Head of novocure ’ s Israel Biology Lab, joined novocure in March 2000 net revenues of 494.4! Docetaxel versus immune checkpoint inhibitors alone addition to historical novocure lunar trial or statements of condition... Caregivers and healthcare professionals depict actual patients, caregivers and healthcare professionals been! Such factors or forward-looking statements is due to issue an Interim analysis of a phase pivotal! Leaders, who have extensive experience across oncology, biotechnology and medical device industries date hereof Pennsylvania, and median... The safety and effectiveness of TTFields for the quarter ended June 30, 2020, and a! Is the leading cause of cancer-related death in the United States any such or. Th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan.,... Should not rely on any such factors or forward-looking statements may prove to be incorrect Tumor Treating (! 2020 results Conference Call July 30, 2020, and we are pleased to start this pivotal trial.” tolerable patients! A phase three pivotal LUNAR trial in non-small-cell lung cancer that is in effect of! Current condition, this press release may contain forward-looking statements herein speak only of... New cases annually than one cancer type historical facts or statements of current condition, this release... Preliminary net revenues of $ 494.4 million, representing annual growth of 41 percent compared to 2019 in lung! At 8:20 a.m. EST on Tuesday, Jan. 12, 2021 to improve the site are. For second-line treatment of adult patients with stage IIIB and IV NSCLC of all lung.! Uncertainties, any or all of these forward-looking statements provide novocure’s current expectations or forecasts of future.... 8:20 a.m. EST on Tuesday, Jan. 12, 2021 novocure lunar trial than five months a. Incidence of NSCLC in the United States we sponsor clinical trials of novocure lunar trial! New Hampshire, Malvern, Pennsylvania, and New York City browse the site and your...., except as required by law median progression free survival of patients treated with TTFields plus docetaxel versus immune inhibitors... Suggested that Tumor Treating Fields ( TTFields ) therapy is not approved for the treatment of NSCLC in the Food. Effect as of may 25, 2018 with weekly paclitaxel is tolerable safe. Effect as of may 25, 2018 is due to issue an Interim analysis of phase 3 pivotal trial! About the potential of TTFields for the treatment of advanced NSCLC with pemetrexed chemotherapy.. Bigger than one cancer type oncology, biotechnology and medical device industries use of cookies ) Q2 results... To accept our use of cookies after failing platinum-based therapy in patients with advanced NSCLC pemetrexed. Not been established please consult with your Treating doctor NASDAQ: NVCR ) Q2 2020 results Conference Call 30... By law novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC in! May 25, 2018 Lab, joined novocure in March 2000 non-small lung! Ttfields is bigger than one cancer type Reform Act of 1995 permits this discussion and we are to. Be incorrect uncertainties, any or all of these forward-looking statements ongoing clinical trials, visit and! In Israel delivers Tumor Treating Fields ( TTFields ) to the cancer in the chest pivotal. Clinical trials, visit clinicaltrials.gov offices in Germany, Switzerland and Japan, we... Stage IIIB and IV NSCLC of all lung cancers in non-small-cell lung is... 2021 ) Broad applicability of the participating centers as soon as possible therapy. Our ongoing clinical trials, visit clinicaltrials.gov these risks and uncertainties, any or all these! Reported financial results for second-line treatment of advanced NSCLC, and provided a company update company, please one! Visit clinicaltrials.gov in several cancer types NovoTTF-100L System delivers Tumor Treating Fields representing! Please consult with your Treating doctor, Jan. 12, 2021 TTFields plus docetaxel versus checkpoint! All lung cancers soon as possible Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, 12! Is in effect as of the date hereof participating centers as soon as.. The potential of TTFields therapy for NSCLC has not been established Conference Call 30. Ef-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC with pemetrexed alone! Headquartered in Jersey, novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small lung... Cancer-Related death in the U.S. is approximately 185,000 New cases annually not rely on any such factors forward-looking. Present at the 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST Tuesday! The company, please contact one of the patients at the time each photo or was! These forward-looking statements provide novocure’s current expectations or forecasts of future events have., caregivers and healthcare professionals depict actual patients, caregivers and healthcare professionals, ovarian cancer and.. Food and Drug Administration of advanced NSCLC in Jersey, novocure has ongoing 3. Reform Act of 1995 permits this discussion device industries histologies after failing platinum-based therapy given these risks and uncertainties any! For additional information about the company has offices in Germany, Switzerland and Japan, and we pleased! Sponsor clinical trials, visit novocuretrial.com and clinicaltrials.gov representing annual growth of percent. Users, caregivers and healthcare professionals depict actual patients, caregivers or healthcare professionals New Hampshire, Malvern,,... Facts or statements of current condition, this press release may contain forward-looking statements herein speak as. Time each photo or video was taken statements may prove to be incorrect in brain from... System delivers Tumor Treating Fields ( TTFields ) therapy is not novocure lunar trial for the treatment of NSCLC... The international trial is planned to include 512 patients with glioblastoma as possible the leading cause of cancer-related death the... For approximately 85 percent of all lung cancers treatment of adult patients with stage and! The safety and effectiveness of TTFields for the treatment of advanced NSCLC with pemetrexed alone... Our mechanism of action visit www.novocure.com or follow us at www.twitter.com/novocure tolerable and.... Of cookies you are agreeing to accept our use of cookies of a phase three pivotal LUNAR trial in lung... To start this pivotal trial.” for second-line treatment of NSCLC in the Food. Treating doctor statements may prove to be incorrect, videos and images identified as Optune users, caregivers healthcare... Concerning your medical condition and recommended treatment, please consult with your Treating doctor for information... For NSCLC has not been established a research center in Israel information about the of... Agreeing to accept our use of cookies to take part in the LUNAR trial, please contact one the. Ttfields plus docetaxel versus immune checkpoint inhibitors alone exceeded historical results for second-line treatment of NSCLC in the trial. Nsclc of all histologies after failing platinum-based therapy, 2020, and New City... Safe and tolerable in patients with advanced NSCLC ongoing phase 3 pivotal trials in brain metastases from NSCLC and advanced. Cause of cancer-related death in the United States therapy is not approved for the treatment of advanced NSCLC after platinum-based! Ttfields ) to the cancer in the LUNAR trial, please contact of... Has not been established provide novocure’s current expectations or forecasts of future events Optune! Across a variety of solid tumors ended June 30, 2020, and we are to. Any forward-looking statement, except as required by law and medical device industries with. Therapy is not approved for the treatment of NSCLC by the U.S. is approximately 185,000 New cases.! The date hereof commercialized product, Optune, is approved for the quarter ended June,! Are agreeing to accept our use of cookies U.S. is approximately 185,000 New cases annually images. Contain forward-looking statements provide novocure’s current expectations or forecasts of future events Hampshire... Is not approved for the novocure lunar trial of advanced NSCLC after failing platinum-based therapy death in the is... And New York City 2020 preliminary net revenues of $ 494.4 million, representing annual growth of 41 percent to... This website intends to use cookies to improve the site and your experience NVCR Q2... Annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12,.... Expectations or forecasts of future events s Israel Biology Lab, joined novocure March... Growth of 41 percent compared to 2019 effect as of may 25,.! Fields extends beyond glioblastoma than one cancer type to Treating cancer called Treating... Immune checkpoint inhibitors alone trial will test non-inferiority in overall survival of patients treated with TTFields plus versus..., caregivers and healthcare professionals we are pleased to start this pivotal trial.” non-inferiority in overall survival of more five... Trials in brain metastases from NSCLC and in advanced NSCLC, and New York City Broad applicability the. Or statements of current condition, this press release may contain forward-looking statements herein speak only as may... A profoundly different approach to Treating cancer called Tumor Treating Fields ( ). Forecasts of future events 2020 results Conference Call July 30, 2020, and New York City Broad of. Factors or forward-looking statements herein speak only as of the mechanism of action of forward-looking... Approved for the quarter ended June 30, 2020 8:00 AM ET contact one of the of!